Protective role of oleic acid against cardiovascular insulin resistance and in the early and late cellular atherosclerotic process

Cardiovasc Diabetol. 2015 Jun 10:14:75. doi: 10.1186/s12933-015-0237-9.

Abstract

Background: Several translational studies have identified the differential role between saturated and unsaturated fatty acids at cardiovascular level. However, the molecular mechanisms that support the protective role of oleate in cardiovascular cells are poorly known. For these reasons, we studied the protective role of oleate in the insulin resistance and in the atherosclerotic process at cellular level such as in cardiomyocytes (CMs), vascular smooth muscle cells (VSMCs) and endothelial cells (ECs).

Methods: The effect of oleate in the cardiovascular insulin resistance, vascular dysfunction, inflammation, proliferation and apoptosis of VSMCs were analyzed by Western blot, qRT-PCR, BrdU incorporation and cell cycle analysis.

Results: Palmitate induced insulin resistance. However, oleate not only did not induce cardiovascular insulin resistance but also had a protective effect against insulin resistance induced by palmitate or TNFα. One mechanism involved might be the prevention by oleate of JNK-1/2 or NF-κB activation in response to TNF-α or palmitate. Oleate reduced MCP-1 and ICAM-1 and increased eNOS expression induced by proinflammatory cytokines in ECs. Furthermore, oleate impaired the proliferation induced by TNF-α, angiotensin II or palmitate and the apoptosis induced by TNF-α or thapsigargin in VSMCs.

Conclusions: Our data suggest a differential role between oleate and palmitate and support the concept of the cardioprotector role of oleate as the main lipid component of virgin olive oil. Thus, oleate protects against cardiovascular insulin resistance, improves endothelial dysfunction in response to proinflammatory signals and finally, reduces proliferation and apoptosis in VSMCs that may contribute to an ameliorated atherosclerotic process and plaque stability.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin II / pharmacology
  • Animals
  • Apoptosis / drug effects
  • Atherosclerosis / metabolism*
  • Blotting, Western
  • Cell Line
  • Cell Proliferation / drug effects
  • Chemokine CCL2 / drug effects
  • Chemokine CCL2 / genetics
  • Chemokine CCL2 / metabolism
  • Inflammation
  • Insulin Resistance*
  • Intercellular Adhesion Molecule-1 / drug effects
  • Intercellular Adhesion Molecule-1 / genetics
  • Intercellular Adhesion Molecule-1 / metabolism
  • MAP Kinase Signaling System / drug effects
  • Mice
  • Muscle, Smooth, Vascular / cytology
  • Muscle, Smooth, Vascular / drug effects*
  • Myocytes, Cardiac / drug effects*
  • Myocytes, Cardiac / metabolism
  • Myocytes, Smooth Muscle / drug effects*
  • NF-kappa B / drug effects
  • NF-kappa B / metabolism
  • Nitric Oxide Synthase Type III / drug effects
  • Nitric Oxide Synthase Type III / genetics
  • Nitric Oxide Synthase Type III / metabolism
  • Oleic Acid / pharmacology*
  • Palmitates / pharmacology
  • Palmitic Acid / pharmacology
  • RNA, Messenger / drug effects*
  • RNA, Messenger / metabolism
  • Reverse Transcriptase Polymerase Chain Reaction
  • Tumor Necrosis Factor-alpha / pharmacology
  • Vasoconstrictor Agents / pharmacology

Substances

  • Ccl2 protein, mouse
  • Chemokine CCL2
  • Icam1 protein, mouse
  • NF-kappa B
  • Palmitates
  • RNA, Messenger
  • Tumor Necrosis Factor-alpha
  • Vasoconstrictor Agents
  • Angiotensin II
  • Intercellular Adhesion Molecule-1
  • Oleic Acid
  • Palmitic Acid
  • Nitric Oxide Synthase Type III
  • Nos3 protein, mouse